American Renal Associates (ARA) stock price, revenue, and financials

American Renal Associates market cap is $210.5 m, and annual revenue was $822.52 m in FY 2019

$210.5 M

ARA Mkt cap, 09-Jul-2020

$193.2 M

American Renal Associates Revenue Q1, 2020
American Renal Associates Net income (Q1, 2020)-2.3 M
American Renal Associates EBIT (Q1, 2020)3.2 M
American Renal Associates Cash, 31-Mar-202062.4 M
American Renal Associates EV917 M

American Renal Associates Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

805.8m822.5m

General and administrative expense

127.6m102.6m101.1m91.1m

Operating expense total

127.6m102.6m101.1m91.1m

Depreciation and amortization

33.9m37.6m39.8m43.8m

EBIT

126.8m106.5m55.3m51.7m

EBIT margin, %

7%6%

Interest expense

35.9m29.3m32.6m

Pre tax profit

87.5m83.9m25.4m8.3m

Income tax expense

(753.0k)8.2m2.9m(17.8m)

Net Income

(385.0k)4.9m(28.8m)26.1m

American Renal Associates Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

100.9m71.5m55.2m34.5m

Accounts Receivable

28.8m79.7m99.5m102.2m

Prepaid Expenses

25.0m28.1m22.3m

Inventories

4.7m4.7m11.4m7.8m

Current Assets

210.4m187.6m194.9m220.0m

PP&E

170.1m168.5m180.3m

Goodwill

573.1m573.4m571.3m538.6m

Total Assets

986.0m964.2m985.8m1.1b

Accounts Payable

31.1m33.4m59.1m49.5m

Short-term debt

48.3m44.5m42.9m60.8m

Current Liabilities

153.8m156.9m197.6m190.9m

Long-term debt

515.6m517.5m672.6m

Total Debt

48.3m44.5m42.9m733.5m

Total Liabilities

710.0m703.8m746.8m875.8m

Common Stock

193.0k196.0k197.0k

Preferred Stock

Additional Paid-in Capital

95.1m67.9m105.7m100.7m

Retained Earnings

(128.6m)(123.8m)(164.5m)(178.2m)

Total Equity

145.7m120.5m109.9m84.5m

Debt to Equity Ratio

0.3 x0.4 x0.4 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

6.8 x8 x9 x12.9 x

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

96.0m93.3m105.1m84.0m74.9m67.6m64.3m69.4m61.9m64.9m69.1m60.2m62.4m

Accounts Receivable

75.8m76.9m77.3m77.5m77.8m81.2m85.7m91.5m90.6m99.3m107.5m103.4m101.8m

Prepaid Expenses

19.5m15.0m13.0m18.2m23.2m17.1m24.5m20.3m20.6m26.5m31.7m27.0m22.9m

Inventories

5.5m4.8m4.5m4.6m5.0m4.7m7.6m6.5m6.4m6.9m7.2m8.0m7.6m

Current Assets

199.5m190.1m204.5m193.8m191.1m178.7m190.0m192.5m184.8m198.1m230.1m212.4m252.7m

PP&E

151.2m160.9m165.1m167.3m165.5m166.9m168.7m167.6m168.3m180.0m161.3m156.2m

Goodwill

569.3m569.9m573.1m573.1m573.1m572.7m570.9m570.9m570.9m577.8m578.2m576.1m538.6m

Total Assets

952.4m953.0m975.3m967.4m964.3m952.4m969.8m975.7m967.1m1.1b1.1b1.1b1.1b

Accounts Payable

23.9m23.5m23.3m24.6m28.2m33.9m40.9m52.8m54.0m46.4m57.6m58.1m57.3m

Short-term debt

49.6m63.3m66.6m68.6m68.9m67.5m68.7m70.5m71.2m71.0m69.3m66.3m60.9m

Current Liabilities

103.6m135.2m150.0m141.3m163.2m153.6m165.1m179.4m179.0m209.3m222.6m211.3m203.1m

Long-term debt

661.4m517.8m520.0m520.4m516.4m514.8m512.8m510.0m506.8m676.8m694.4m681.5m707.9m

Total Debt

27.2m40.6m43.6m45.6m45.7m44.2m45.1m46.7m47.2m747.8m763.7m747.8m768.9m

Total Liabilities

790.0m698.3m703.7m692.7m710.2m697.2m710.3m733.9m724.5m902.8m934.2m908.9m922.6m

Common Stock

98.0k184.0k184.0k184.0k185.0k186.0k195.0k195.0k195.0k197.0k197.0k197.0k199.0k

Preferred Stock

Additional Paid-in Capital

457.0k72.4m69.8m93.6m95.4m94.2m68.6m69.2m66.0m104.4m103.3m104.7m102.8m

Retained Earnings

(124.5m)(133.6m)(121.5m)(129.9m)(132.0m)(124.0m)(124.5m)(142.5m)(140.0m)(174.9m)(183.1m)(178.3m)(185.5m)

Total Equity

55.0m119.9m131.3m142.2m140.1m144.2m110.7m96.3m92.4m102.3m88.8m84.7m73.8m

Debt to Equity Ratio

0.5 x0.3 x0.3 x0.3 x0.3 x0.3 x0.4 x0.5 x0.5 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x

Financial Leverage

17.3 x7.9 x7.4 x6.8 x6.9 x6.6 x8.8 x10.1 x10.5 x11.1 x12.9 x13.2 x15.2 x

American Renal Associates Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

88.2m75.7m22.5m26.1m

Depreciation and Amortization

33.9m37.6m39.8m43.8m

Accounts Receivable

(4.2m)1.5m13.1m(2.6m)

Inventories

(385.0k)11.0k(6.8m)3.7m

Accounts Payable

8.6m2.3m25.7m(9.5m)

Cash From Operating Activities

172.2m128.5m106.4m38.8m

Purchases of PP&E

(61.4m)(36.1m)(45.0m)(23.1m)

Cash From Investing Activities

(35.3m)(42.8m)(20.3m)

Long-term Borrowings

(275.2m)(327.3m)(90.4m)(54.1m)

Dividends Paid

(30.2m)(8.7m)(332.0k)(50.0k)

Cash From Financing Activities

(122.5m)(79.9m)(39.3m)

Net Change in Cash

(29.3m)(16.3m)(20.8m)

Interest Paid

32.5m26.8m30.5m34.2m

Income Taxes Paid

16.1m1.9m2.6m2.2m

American Renal Associates Ratios

USDQ1, 2016

Debt/Equity

0.5 x

Financial Leverage

17.3 x

American Renal Associates Employee Rating

2.7170 votes
Culture & Values
2.9
Work/Life Balance
3
Senior Management
2.5
Salary & Benefits
2.9
Career Opportunities
2.7
Source